Key Takeaways AstraZeneca's anselamimab missed the primary endpoint in both phase III CARES studies for AL amyloidosis. The drug showed a clinically meaningful benefit in a prespecified subgroup, but details remain undisclosed. AZN plans a full analysis of the data and will present findings at an upcoming medical meeting.AstraZeneca (AZN) reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare ...

智通财经7月16日电，阿斯利康股价下跌1%，因Anselamimab未能在晚期临床试验中达到主要目标。 ...

阿斯利康一款药物未能达到研究的主要目标 金十数据7月16日讯，阿斯利康周三表示，其实验性药物Anselamimab没有达到治疗AL淀粉样变性疾病 的晚期研究的主要目标。AL淀粉样变性是一种罕见的疾病，会导致体内蛋白质沉积增多，造成重大器 官损伤。 ...